M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Forest Laboratories acquires extended US market pediatric exclusivity for NAMENDA and NAMENDA XR by six months
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Wednesday that it has received the US Food and Drug Administration's (FDA) pediatric exclusivity for memantine hydrochloride.
Following the US FDA's decision, an additional six months of US market exclusivity will attach to the...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives